Browse Studies — Arctuva

Phase 1

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of JUR-003 in Adult Patients With Metastatic Prostate Cancer

JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-…

Metastatic Castration Resistant Prostate CancerOligometastatic Prostate Cancer (OMPC)Metastatic Hormone Sensitive Prostate Cancer

Estimated

~$10 – $8,750

Juri Biosciences, Inc.NCT07824349

Phase 3

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prosta…

Oligometastatic Prostate Cancer (OMPC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT05939414

Phase 2

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination wi…

Oligometastatic Prostate Cancer

Estimated

~$10 – $7,500

Catherine SpinaNCT05915442

Phase 1

Pilot Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and PD-1 Blockade, With Targeted Ablation of Resistant Lesions, in Patients With Non-Castrate Recurrent Oligometastatic Prostate Cancer

The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab …

Prostate Cancer PatientsNon-castrate Prostate CancerRecurrent Prostate Cancer+1 more

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT07090148